<DOC>
	<DOCNO>NCT02946554</DOCNO>
	<brief_summary>The study assess safety two dose regimen HepaStem Patients ACLF Day 28 active study period .</brief_summary>
	<brief_title>Phase II Safety Study 2 Dose Regimens HepaStem Patients With ACLF</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>Main Diagnosed cirrhosis ACLF Grade 1 ACLF Grade 2 circulatory respiratory failure . Main Absence portal vein flow Known medical history thrombotic event Gastrointestinal hemorrhage require blood transfusion Septic shock noncontrolled bacterial infection Clinical evidence aspergilus infection . Circulatory failure Respiratory disorder MELD score &gt; 35 . Previous organ transplantation and/or ongoing immunosuppressive treatment . Renal failure due chronic kidney disease . Clinically significant leftright cardiac shunt .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute-On-Chronic Liver Failure</keyword>
	<keyword>ACLF</keyword>
</DOC>